ECSP17070706A - Inhibidores de bromodominio - Google Patents

Inhibidores de bromodominio

Info

Publication number
ECSP17070706A
ECSP17070706A ECIEPI201770706A ECPI201770706A ECSP17070706A EC SP17070706 A ECSP17070706 A EC SP17070706A EC IEPI201770706 A ECIEPI201770706 A EC IEPI201770706A EC PI201770706 A ECPI201770706 A EC PI201770706A EC SP17070706 A ECSP17070706 A EC SP17070706A
Authority
EC
Ecuador
Prior art keywords
compositions
compounds
bromodominium
inhibitors
bromodomain
Prior art date
Application number
ECIEPI201770706A
Other languages
English (en)
Inventor
Stephen Kaldor
Michael John; Bennett
Jeffrey Stafford
Juan Manuel Betancort
James Veal
Amogh Boloor
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of ECSP17070706A publication Critical patent/ECSP17070706A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos derivados heterocíclicos sustituidos, composiciones que comprenden los compuestos mencionados, y el uso de dichos compuestos y composiciones para la regulación epigenética por inhibición del reconocimiento mediado por bromodominios de regiones acetil lisina de proteínas, como las histonas. Dichas composiciones y métodos son útiles para el tratamiento de cáncer y enfermedades neoplásicas.
ECIEPI201770706A 2015-04-15 2017-10-24 Inhibidores de bromodominio ECSP17070706A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562148098P 2015-04-15 2015-04-15

Publications (1)

Publication Number Publication Date
ECSP17070706A true ECSP17070706A (es) 2017-12-01

Family

ID=57126317

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201770706A ECSP17070706A (es) 2015-04-15 2017-10-24 Inhibidores de bromodominio

Country Status (21)

Country Link
US (3) US9908885B2 (es)
EP (2) EP3831383A1 (es)
JP (1) JP6856543B2 (es)
KR (1) KR20170135938A (es)
CN (1) CN107635558A (es)
AR (1) AR104259A1 (es)
AU (1) AU2016249273B2 (es)
CA (1) CA2982588A1 (es)
CL (1) CL2017002606A1 (es)
CO (1) CO2017011484A2 (es)
EA (1) EA201792229A1 (es)
EC (1) ECSP17070706A (es)
ES (1) ES2868355T3 (es)
HK (1) HK1243326A1 (es)
IL (1) IL255006A0 (es)
MX (1) MX2017013207A (es)
PE (1) PE20180258A1 (es)
PH (1) PH12017501888A1 (es)
SG (1) SG11201708470SA (es)
TW (1) TW201643153A (es)
WO (1) WO2016168682A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
JP2018527340A (ja) 2015-08-11 2018-09-20 ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ アリール置換ジヒドロキノリノン、その調製及び医薬品としてのその使用
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
CA2994478C (en) 2015-08-12 2023-10-03 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN108314680A (zh) * 2017-01-16 2018-07-24 凯惠科技发展(上海)有限公司 一种含芳环化合物、其制备方法、药物组合物及应用
TW202332436A (zh) 2017-04-18 2023-08-16 美商塞爾基因定量細胞研究公司 治療用化合物
CN107098844B (zh) * 2017-05-17 2019-07-30 许昌学院 一种c-5位硝基取代的酰基吲哚啉类化合物的合成方法
WO2019120234A2 (zh) * 2017-12-20 2019-06-27 贝达药业股份有限公司 作为溴结构域蛋白质抑制剂的化合物和组合物
JP2021512167A (ja) 2018-01-30 2021-05-13 フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 障害を治療するための方法及び化合物
CN108516973A (zh) * 2018-03-30 2018-09-11 广西师范大学 3-苯并噻唑-1-(3-二甲氨基)丙基喹啉-4-酮衍生物及其制备方法和应用
KR20210058817A (ko) * 2018-07-23 2021-05-24 셀젠 콴티셀 리서치, 인크. 브로모도메인 억제제의 제조 방법
HUE066335T2 (hu) 2018-10-05 2024-07-28 Annapurna Bio Inc Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére
CN113226322A (zh) 2018-10-30 2021-08-06 诺维逊生物股份有限公司 作为bet抑制剂的杂环化合物
CN113874016A (zh) * 2019-01-29 2021-12-31 福宏治疗公司 化合物及其用途
WO2020160198A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160193A2 (en) * 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
JP2022053557A (ja) * 2019-02-08 2022-04-06 マルホ株式会社 ピリドン誘導体
US12497395B2 (en) * 2019-04-24 2025-12-16 Convergene, Llc Small molecule bromodomain inhibitors and uses therof
JP7465945B2 (ja) * 2019-07-02 2024-04-11 ニューベイション・バイオ・インコーポレイテッド Ｂｅｔ阻害剤としてのヘテロ環式化合物
CN112174945B (zh) * 2019-07-02 2022-06-07 四川大学 具有抗癌作用的吲唑类化合物及其制备方法和用途
US20220289711A1 (en) * 2019-07-31 2022-09-15 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155100A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155225A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
EP4188447A1 (en) * 2020-07-29 2023-06-07 Foghorn Therapeutics Inc. Compounds and uses thereof
US12527741B2 (en) 2021-06-17 2026-01-20 Wisconsin Alumni Research Foundation Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
CN114014842B (zh) * 2021-11-04 2024-03-01 中国药科大学 一种杂环酮类化合物与其组合物及其制备方法和应用
WO2023090859A1 (ko) * 2021-11-17 2023-05-25 일동제약(주) 아이속사졸 유도체의 제조 방법 및 그의 신규한 중간체
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1349418A (en) * 1919-08-05 1920-08-10 George F Flynn Motor-support
US3590036A (en) * 1968-11-18 1971-06-29 George Y Lesher Naphthyridine-3-carboxylic acids,their derivatives and preparation thereof
DE2011970A1 (en) 1970-03-13 1971-11-18 CH. Boehringer Sohn, 6507 Ingelheim Imidazo-(1, 2-a)- pyrimidines prepn
US3635667A (en) 1970-07-23 1972-01-18 Fmc Corp Drycleaning with hydrogen peroxide
GB1322318A (en) * 1971-05-19 1973-07-04 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids and esters
BE786028A (fr) 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2356005A1 (de) 1973-11-09 1975-05-22 Boehringer Sohn Ingelheim Neue 7-amino-imidazo eckige klammer auf 1,2-a eckige klammer zu pyrimidine, diese enthaltende arzneimittel sowie verfahren zu deren herstellung
AU577105B2 (en) 1985-04-02 1988-09-15 T.P.O. :Pharmachim: Acylaminic penicillin derivatives
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
MXPA02012314A (es) * 2000-06-12 2004-09-06 Eisai Co Ltd Compuestos de 1,2-dihidropiridina, metodo de fabricacion y utilizacion de los mismos.
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
EP1556381B1 (en) 2002-09-26 2008-02-20 Pfizer Limited Pyrazole amides for treating hiv infections
JP2005089352A (ja) 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
JP4824563B2 (ja) * 2003-09-23 2011-11-30 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリンカリウムチャネル阻害剤
WO2005030791A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
KR100703068B1 (ko) 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
CA2562126A1 (en) 2004-04-01 2005-10-13 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
KR100781704B1 (ko) 2005-04-20 2007-12-03 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
HRP20110839T1 (hr) 2005-07-26 2011-12-31 Sanofi Derivati cikloheksaminizokinolona kao inhibitori rho-kinaze
PT1910333E (pt) 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
US20070099911A1 (en) 2005-10-28 2007-05-03 Wyeth Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands
AU2007225273A1 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
GB0612428D0 (en) * 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
MY150746A (en) 2006-12-27 2014-02-28 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
RU2468011C2 (ru) 2006-12-27 2012-11-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолина и изохинолинона
JP5405314B2 (ja) 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノロン誘導体
US20090054434A1 (en) 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
CA2712897A1 (en) 2008-01-30 2009-08-06 Pharmacopeia, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
JP5433691B2 (ja) 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体
WO2010039186A2 (en) * 2008-09-23 2010-04-08 Renovis, Inc. Compounds useful as faah modulators and uses thereof
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2379564A1 (en) * 2008-12-19 2011-10-26 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
EP2485731B1 (en) 2009-10-06 2016-05-11 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as pdk1 inhibitors
US8754113B2 (en) 2009-12-15 2014-06-17 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
SG186855A1 (en) 2010-06-28 2013-02-28 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
WO2012086735A1 (ja) * 2010-12-22 2012-06-28 大正製薬株式会社 縮合複素環化合物
US9884828B2 (en) 2011-05-23 2018-02-06 Imago Pharmaceuticals, Inc. Substituted cinnolines as inhibitors of LRRK2 kinase activity
RU2477723C2 (ru) * 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
EP2773641B1 (en) 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
CN103183675A (zh) 2011-12-27 2013-07-03 山东轩竹医药科技有限公司 磷酸二酯酶-4抑制剂
US9434743B2 (en) * 2012-03-02 2016-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
US9550737B2 (en) 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
JP2014024838A (ja) * 2012-06-21 2014-02-06 Taisho Pharmaceutical Co Ltd 縮合複素環化合物を有効成分として含有する血糖低下作用薬
EP2875007B1 (en) * 2012-07-19 2016-08-24 Bristol-Myers Squibb Company Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
CN104903320B (zh) 2013-01-11 2018-11-13 富士胶片株式会社 含氮杂环化合物或其盐
EP2970312B1 (en) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
JP6325078B2 (ja) * 2013-03-15 2018-05-16 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ヘテロ環式化合物およびその使用
CN105209467B (zh) * 2013-05-27 2018-06-08 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
WO2014205594A1 (en) * 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases
MX355943B (es) * 2013-06-26 2018-05-07 Abbvie Inc Carboxamidas primarias como inhibidores de btk.
AU2014337064B2 (en) * 2013-10-18 2019-03-14 Celgene Quanticel Research, Inc. Bromodomain inhibitors
US9315501B2 (en) * 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9920052B2 (en) 2013-12-09 2018-03-20 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
WO2015105749A1 (en) * 2014-01-07 2015-07-16 Bristol-Myers Squibb Company Sulfone amide linked benzothiazole inhibitors of endothelial lipase
AU2015209189A1 (en) * 2014-01-24 2016-07-28 Confluence Life Sciences, Inc. Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases
UA119870C2 (uk) * 2014-04-23 2019-08-27 Інсайт Корпорейшн 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET
MA40943A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
CN107531690B (zh) * 2014-11-27 2020-11-06 基因泰克公司 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
WO2016139361A1 (en) * 2015-03-05 2016-09-09 Boehringer Ingelheim International Gmbh New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑

Also Published As

Publication number Publication date
HK1243326A1 (zh) 2018-07-13
JP6856543B2 (ja) 2021-04-07
IL255006A0 (en) 2017-12-31
CA2982588A1 (en) 2016-10-20
WO2016168682A3 (en) 2016-12-08
TW201643153A (zh) 2016-12-16
US20200071332A1 (en) 2020-03-05
US10494371B2 (en) 2019-12-03
AU2016249273B2 (en) 2020-07-09
MX2017013207A (es) 2018-02-19
US20170050968A1 (en) 2017-02-23
ES2868355T3 (es) 2021-10-21
WO2016168682A2 (en) 2016-10-20
AR104259A1 (es) 2017-07-05
JP2018511626A (ja) 2018-04-26
PE20180258A1 (es) 2018-02-05
EA201792229A1 (ru) 2018-05-31
AU2016249273A1 (en) 2017-11-09
SG11201708470SA (en) 2017-11-29
CL2017002606A1 (es) 2018-05-18
KR20170135938A (ko) 2017-12-08
EP3283077A4 (en) 2019-01-23
PH12017501888A1 (en) 2018-03-05
US20180134710A1 (en) 2018-05-17
US9908885B2 (en) 2018-03-06
EP3831383A1 (en) 2021-06-09
CO2017011484A2 (es) 2018-01-31
EP3283077B1 (en) 2021-03-10
CN107635558A (zh) 2018-01-26
EP3283077A2 (en) 2018-02-21
US10807982B2 (en) 2020-10-20

Similar Documents

Publication Publication Date Title
ECSP17070706A (es) Inhibidores de bromodominio
NI201600056A (es) Inhibidores de bromodominio
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX2016014253A (es) Inhibidores de desmetilasa-1 especifica de lisina.
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
MX2018005696A (es) Tratamiento de la osteoartritis.
UY35975A (es) Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia
MX2017000450A (es) Compuestos terapeuticos inhibidores.
CL2019003515A1 (es) Compuestos heteroaromáticos como inhibidores de vanina.
MX385138B (es) Inmunomoduladores de aminoacilindazol para el tratamiento de enfermedades autoinmunes.
MX2018010993A (es) Derivados de icariina e icaritina.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX388564B (es) Compuestos de indolinona y usos de los mismos.
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam